Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | CD44 | P16070 | 2/20 | 0.37 |
| ▸ | PNMT | P11086 | 5/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.34 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26703722 | 0.85 | PNMT (0.37) | MEN1GABRA1CYP2C19GABRB2KMT2A | |
| SCHEMBL9594487 | 0.75 | DRD4 (0.46) | SLC2A1 | |
| SCHEMBL1009530 | 0.75 | DRD4 (0.42) | SLC2A1 | |
| SCHEMBL7377305 | 0.74 | PNMT (0.35) | MEN1KMT2ACD44PNMTMAOB | |
| SCHEMBL18822678 | 0.73 | DRD4 (0.41) | SLC2A1 | |
| SCHEMBL164154 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL2743974 | 0.71 | PNMT (0.39) | CD44PNMTMAOBADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL5465421 | 0.71 | PNMT (0.39) | CD44PNMTMAOBADRA2AADRA2B | |
| Ammonia Solution, Strong SCHEMBL1764117 | 0.71 | PNMT (0.39) | CD44PNMTMAOBADRA2AADRA2B | |
| SCHEMBL30458186 | 0.70 | NISCH (0.46) | MEN1GABRA1CYP2C19GABRB2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3652180-B1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-11-29 | — | — | EP | claimed |
| US-11685745-B2 | Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors | DART NEUROSCIENCE, LLC (US) | 2023-06-27 | — | — | US | claimed |
| US-20220267351-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE, LLC | 2022-08-25 | — | — | US | claimed |
| EP-3652180-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | Dart NeuroScience LLC (US) | 2020-05-20 | — | — | EP | claimed |
| WO-2019014305-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2019-01-17 | — | — | WO | claimed |
| US-20260048059-A1 | USE OF SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANC | WIRTH KLAUS (DE) | 2026-02-19 | — | — | US | disclosed |
| WO-2025264837-A1 | NAPHTHYRIDINE GPR52 MODULATORS AND METHODS OF USE THEREOF | LIEBER INSTITUTE, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-4572766-A1 | USE OF SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024038090-A1 | USE OF SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-22 | — | — | WO | disclosed |
| EP-3652180-B1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230295178-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-09-21 | — | — | US | disclosed |
| US-11685745-B2 | Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors | DART NEUROSCIENCE, LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-10800786-B2 | Bicyclic compounds as ATX inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3652180-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | Dart NeuroScience LLC (US) | 2020-05-20 | — | — | EP | disclosed |
| US-20200087307-A1 | BICYCLIC COMPOUNDS AS ATX INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20190177327-A1 | SUBSTITUTED METHYL PYRAZOLOPYRIMIDINONE AND METHYL IMIDAZOPYRAZINONE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2019-06-13 | — | — | US | disclosed |
| WO-2019104285-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2019-05-31 | — | — | WO | disclosed |
| WO-2019014305-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2019-01-17 | — | — | WO | disclosed |
| WO-2019014305-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2019-01-17 | — | — | WO | disclosed |
| US-20180312515-A1 | NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800786-B2 | Bicyclic compounds as ATX inhibitors | ATXN2, ATXN2L, ATXN10 | MEN1 1737/4885GABRA1 3178/4885CYP2C19 4146/4885 |
| US-20180312515-A1 | NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS | ATXN2, ATXN2L, ATXN10 | MEN1 1601/4885GABRA1 3012/4885CYP2C19 4163/4885 |
| US-11685745-B2 | Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors | PDE7A, PDE7B, PDE8B | MEN1 3813/4885GABRA1 97/4885CYP2C19 174/4885 |
| US-20260048059-A1 | USE OF SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANC | FANCF, EPAS1, PDE4C | MEN1 711/4885GABRA1 1360/4885CYP2C19 487/4885 |
| US-20230295178-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | PDE4A, PDE5A, PDE3A | MEN1 1930/4885GABRA1 2487/4885CYP2C19 708/4885 |
| US-20190177327-A1 | SUBSTITUTED METHYL PYRAZOLOPYRIMIDINONE AND METHYL IMIDAZOPYRAZINONE COMPOUNDS AS PDE1 INHIBITORS | PDE3A, PDE5A, PDE4A | MEN1 1195/4885GABRA1 2177/4885CYP2C19 768/4885 |
| US-20200087307-A1 | BICYCLIC COMPOUNDS AS ATX INHIBITORS | ATXN2, ATXN2L, ATXN10 | MEN1 1737/4885GABRA1 3178/4885CYP2C19 4146/4885 |
| US-20220267351-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | PDE7A, PDE7B, PDE8B | MEN1 3813/4885GABRA1 97/4885CYP2C19 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.